The development of gene-inactivation systems is an active and important field for both functional genomics and gene therapy. Towards this end, ribozymes (i.e. RNA enzymes), that specifically recognize and subsequently catalyze the cleavage of other target RNA molecules, are attractive molecular tools. Ribozymes represent an interesting alternative to the RNA interference (RNAi) approach for gene inactivation, especially given the fact that RNAi seems to trigger an immunological response and has demonstrated off-target effects. However, the design and optimization of a ribozyme-based gene-inactivation system is not a straightforward procedure. Several aspects need to be considered in the experimental design in order to provide a suitable suppression system. In this review we present the advances in this domain made available from work using the hepatitis delta virus (HDV) ribozyme as a cis-acting RNA motif in molecular biology, as well as a trans-acting molecular scissor for the development of a gene-inactivation system. This HDV ribozyme technology possesses several unique features that are all related to the fact that it is the only catalytic cleaving RNA motif that has been discovered in humans.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2174/156652307780859008 | DOI Listing |
Aliment Pharmacol Ther
January 2025
Division of Gastroenterology and Hepatology, University of Alberta Hospital, University of Alberta, Edmonton, Alberta, Canada.
Aliment Pharmacol Ther
January 2025
Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.
Clin Infect Dis
January 2025
Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Background: Tenofovir-containing antiretroviral therapy (ART) improves survival in HBV-coinfected people with HIV (PWH). We investigated the incidence of HDV infection and its clinical impact in HBV-coinfected PWH in the era of tenofovir-containing ART.
Methods: Between 2011 and 2022, HBV-coinfected PWH were included and followed until December 2023.
Hepatology
December 2024
Department of Clinical Pharmacy, Xiangtan Central Hospital(The affiliated hospital of Hunan university), Xiangtan 411100, China.
J Viral Hepat
January 2025
Department of Gastroenterology and Hepatology, Koç University Medical School, Istanbul, Turkey.
In coronavirus disease 2019 (COVID-19), older age and co-morbidities are associated with mortality. Among liver disease aetiologies alcoholic liver disease was associated with mortality. Chronic hepatitis delta (CHD) had not been studied.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!